Skip to content
Home/Companies/Biotech/Ducentis BioTherapeutics
DB

Ducentis BioTherapeutics

Biotech·UK·Exited 2022·Held 3yr

Ducentis BioTherapeutics is a biotech company, headquartered in UK.

Entry
2019
Hold
3yr
Exit
2022
Est. EV
–

Who owns Ducentis BioTherapeutics?

Ducentis BioTherapeutics was owned by LifeArc through LifeArc Ventures (1992 vintage) from 2019 to 2022, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-05-31

LifeArc
Investor
LifeArc
LifeArc Ventures · 1992 · Life Sciences VC

Key facts

HQUK
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2022

More from LifeArc Ventures

Other portfolio companies in the same fund.

Fluid Biomed
Active
MedTechCanada· 2024
Affect Therapeutics
Active
HealthTechUnited States· 2023
Cytospire Therapeutics
Active
BiotechUK· 2023
Maxion Therapeutics
Active
BiotechUK· 2023
Ozlo Sleep
Active
HealthTechUnited States· 2023
RQ Biotechnology
Active
BiotechUK· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings